Sutro completed its review as it widened its loss and posted lower revenue in 2024. The company posted a loss of $227.5 million last year, compared with a loss of $106.8 million in 2023. On a per-share basis, the company's loss came in at $2.96, compared with the $2.90 loss that analysts surveyed by FactSet expected.

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner - - Three INDs for wholly